Stocks Health care PBYI
NASDAQ · Health carePuma Biotechnology, Inc. (PBYI)
Puma Biotechnology, Inc. brought in $231.8M of revenue over the twelve months to September 30, 2026, up 9.4% from a year earlier. Net income was $23.8M, a net margin of 10.3%. Operating cash flow minus capital spending left $41.7M of free cash flow in fiscal 2025. At September 30, 2026 it held $41.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Puma Biotechnology, Inc.
- Net worth
- Puma Biotechnology, Inc. has a market value (market cap) of $426.4M at the latest share price, and shareholders' equity of $146.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $228.4M (-0.9% year on year), with net income of $31.1M. Over the 12 months to September 30, 2026: revenue $231.8M, net income $23.8M.
- Cash flow
- In fiscal 2025 operations brought in $41.8M of cash; after $71K of capital spending, free cash flow was $41.7M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Puma Biotechnology, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Puma Biotechnology, Inc. does
Puma Biotechnology, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PBYI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $228.4M | $31.1M | $0.61 | $41.7M |
| 2024 | $230.5M | $30.3M | $0.62 | $38.9M |
| 2023 | $235.6M | $21.6M | $0.45 | $26.9M |
| 2022 | $228M | $2K | $0.00 | -$15.8M |
| 2021 | $253.2M | -$29.1M | -$0.72 | $20.7M |
| 2020 | $225.1M | -$60M | -$1.52 | $727K |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where PBYI ranks in Health care
Latest SEC filings
What Puma Biotechnology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 1.1% to $55.1M versus the same quarter last year; diluted EPS $0.11 versus $0.17.
- November 5, 2026
- October 6, 2026Activist stake changed SCHEDULE 13D/A
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 7.8% to $56.5M versus the same quarter last year; diluted EPS $0.16 versus $0.12.
- August 6, 2026
- June 16, 2026
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 2.6% to $44.8M versus the same quarter last year; diluted EPS -$0.07 versus $0.06.
- May 7, 2026
- April 28, 2026Additional proxy material DEFA14A
- April 28, 2026
What is PBYI worth? A DCF from its reported cash flow
Insider trades
What the people running Puma Biotechnology, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $612.5K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 14, 2026 | Cesano AlessandraDirector | Exercised options | 50,000 | $146.5K |
| September 14, 2026 | Cesano AlessandraDirector | Soldpre-planned (10b5-1) | 62,150 | $567K |
| September 14, 2026 | Wilson Troy EdwardDirector | Soldpre-planned (10b5-1) | 5,000 | $45.5K |
| July 6, 2026 | Nougues Maximo FChief Financial Officer | Soldpre-planned (10b5-1) | 9,386 | $77.6K |
| July 6, 2026 | Hunt Douglas MSee Remarks | Soldpre-planned (10b5-1) | 8,460 | $69.9K |
| July 6, 2026 | Auerbach Alan HPresident and CEO, Director, 10% owner | Soldpre-planned (10b5-1) | 44,058 | $364.1K |
| June 12, 2026 | Dorval AllisonDirector | Soldpre-planned (10b5-1) | 11,610 | $83.6K |
| June 12, 2026 | Moyes Jay MDirector | Soldpre-planned (10b5-1) | 22,000 | $158.8K |
Who owns PBYI
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Alan H. Auerbach13D, may seek influence | 16% | October 6, 2026 |
| Anders Hove13G, passive with 4 related filers | 8% | February 14, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 161 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Acorn Capital Advisors, LLC | 4,131,299 | 0 |
| BlackRock, Inc. | 3,804,736 | +205,784 |
| American Century Companies Inc | 2,319,996 | +403,650 |
| Renaissance Technologies LLC | 1,836,213 | -106,200 |
| Vanguard Capital Management LLC | 1,835,643 | +17,962 |
| Vanguard Portfolio Management LLC | 1,825,599 | +90,950 |
| Dimensional Fund Advisors LP | 1,518,014 | +81,908 |
| Geode Capital Management, LLC | 1,339,405 | +322,063 |
| O'Shaughnessy Asset Management, LLC | 1,123,783 | -14,386 |
| State Street Corp | 952,165 | +34,575 |
| Kennedy Capital Management LLC | 873,253 | -16,348 |
| Bridgeway Capital Management, LLC | 791,616 | +16,275 |
| Ritholtz Wealth Management | 749,798 | -24,510 |
| Aqr Capital Management LLC | 725,192 | -75,002 |
| Goldman Sachs Group Inc | 669,156 | -563 |
| Northern Trust Corp | 652,386 | +10,633 |
| Connor, Clark & Lunn Investment Management Ltd. | 642,946 | -139,852 |
| UBS Group AG | 636,761 | +102,534 |
| Millennium Management LLC | 602,240 | -875,279 |
| Arrowstreet Capital, Limited Partnership | 532,450 | -5,705 |
Insiders
10 insiders reported holding 8,171,559 shares in total, about $67.5M at the last price.
| Holder | Shares |
|---|---|
| Auerbach Alan HPresident and CEO, Director, 10% owner | 7,261,671 |
| Nougues Maximo FChief Financial Officer | 230,637 |
| Hunt Douglas MSee Remarks | 196,841 |
| Stuglik Brian MDirector | 113,858 |
| Dorval AllisonDirector | 90,780 |
| Miller Michael PatrickDirector | 81,000 |
| Moyes Jay MDirector | 58,322 |
| Cesano AlessandraDirector | 56,700 |
| Wilson Troy EdwardDirector | 54,750 |
| Senderowicz AdrianDirector | 27,000 |
Questions about PBYI
What does Puma Biotechnology, Inc. do?
Puma Biotechnology, Inc. is a company in the Health care sector, listed on NASDAQ as PBYI. Its shares trade on NASDAQ under the ticker PBYI.
What is Puma Biotechnology, Inc.'s net worth?
Puma Biotechnology, Inc. has a market value (market cap) of $426.4M at the latest share price, and shareholders' equity of $146.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Puma Biotechnology, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $23.8M on revenue of $231.8M, a net margin of 10.3%.
How much revenue does Puma Biotechnology, Inc. make?
Over the twelve months to September 30, 2026 Puma Biotechnology, Inc. reported revenue of $231.8M. That is 9.4% more than a year earlier.
When did Puma Biotechnology, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Puma Biotechnology, Inc.'s next earnings report?
Puma Biotechnology, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PBYI with
Follow PBYI
Get an email when Puma Biotechnology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Puma Biotechnology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.